biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > $5.25 million

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Mar 01, 2023 10:39am

135 Views

Post# 35312351

RE:RE:$5.25 million

fuzzyjr wrote: Somethings got to give soon.
glts

It will be interesting. Is BTI a zero or hero?

There are a number of different possibilities to add value at $.02 as has been outlined.

I originally hoped for a Saltarelli - a deal consistent with Saltarelli's historic success. He's chosen to stay with BTI when he could easily go elsewhere. He's said xB3 should be able to perform equal to or better than DNLI. We have the validation from Chiesi, and the multi-product option from the word's largest healthcare company(J&J). Saltarelli is on Chiesi's xB3 Advisory Board and again he's stayed with BTI and Lysosomal Storage has become a strategic focus.

Then we had a potential Saltarelli on steriods in the Biodexa deal which the former Group Finance Director of Shire challenged anyone to find more opportunity than at its market cap. WoW! Successfull fund Armistice Group wanted the whole Biodexa financing. BTI was more highly valued than Midatech in the Biodexa deal and Midatech has secured a financing.

Zero or hero? It all depends on execution. Rathjen aimed for the stars with the Biodexa deal. Can she put an alternative together with limited time and resources?

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale